.png){kind=icon}
.png){kind=icon}
Return
Out of Sight, Hiding in Plain Clues
.png){kind=icon}
PRE
AI
DOI：10.1016/j.survophthal.2025.11.006.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
A 76-year-old man with advanced non-small cell lung carcinoma, undergoing treatment with carboplatin and paclitaxel plus pembrolizumab, presented to the emergency department with a one-week history of rapidly progressive, severe bilateral visual loss and pain on eye movement. Ocular movements were full, with no other neurological deficits noted. Visual acuity was reduced bilaterally 20/63 right eye, 20/200 left eye. Color vision testing was borderline normal, bilateral visual fields were constricted, while both fundoscopy and optical coherence tomography (OCT) were unremarkable. An urgent MRI of the brain revealed patchy FLAIR hyperintensities in both optic nerves and faint post-contrast enhancement. By the time of neurological assessment one week later, the patient had experienced partial spontaneous improvement in vision. A comprehensive neuro-oncological differential diagnosis was performed, prompting the request for further diagnostic tests. This case illustrates the evolving landscape of neuro-oncology, where advances in diagnostic approaches and the use of immunotherapies such as pembrolizumab may alter immune tolerance, leading to immune-related adverse events such as MOG antibody-associated disease.
Journal
IF:
5.9
Papers:
2.3K
Citations:
7.8K